Cargando…

Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells

Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the effect of radiation (XRT) by impairing the DNA damage repair process. This study aimed to identify a radiosensitive gene signature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghashghaei, Maryam, Niazi, Tamim M., Aguilar-Mahecha, Adriana, Klein, Kathleen Oros, Greenwood, Celia M. T., Basik, Mark, Muanza, Thierry M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586860/ https://www.ncbi.nlm.nih.gov/pubmed/31221986 http://dx.doi.org/10.1038/s41598-019-44991-w

Ejemplares similares

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway
por: Sekhar, Konjeti R., et al.
Publicado: (2019)

A micro-flow, high-pH, reversed-phase peptide fractionation and collection system for targeted and in-depth proteomics of low-abundance proteins in limiting samples
por: Zurawska, Marta, et al.
Publicado: (2023)

The Effect of Pre-Analytical Variability on the Measurement of MRM-MS-Based Mid- to High-Abundance Plasma Protein Biomarkers and a Panel of Cytokines
por: Aguilar-Mahecha, Adriana, et al.
Publicado: (2012)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker
por: Aguilar-Mahecha, Adriana, et al.
Publicado: (2009)

Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report
por: Aguilar-Mahecha, Adriana, et al.
Publicado: (2019)

Hormone Excretion in Prostatic Cancer: An Attempt to Correlate Urinary Hormone Excretion and Clinical State
por: Bulbrook, R. D., et al.
Publicado: (1959)

Effect of hormones on the variation of radiosensitivity in females as measured by induction of chromosomal aberrations.
por: Roberts, C J, et al.
Publicado: (1997)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
por: Freedland, Stephen J, et al.
Publicado: (2021)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Chromosome-breakage genomic instability and chromothripsis in breast cancer
por: Przybytkowski, Ewa, et al.
Publicado: (2014)

Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis
por: Lu, Tianyuan, et al.
Publicado: (2019)

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
por: Iguchi, Taro, et al.
Publicado: (2021)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer
por: Fan, Huihui, et al.
Publicado: (2023)

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations
por: Oros Klein, Kathleen, et al.
Publicado: (2016)

Ensemble Learning for Hormone Binding Protein Prediction: A Promising Approach for Early Diagnosis of Thyroid Hormone Disorders in Serum
por: Butt, Ahmad Hassan, et al.
Publicado: (2023)

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
por: Wang, Xiaofang, et al.
Publicado: (2016)

High Systolic Blood Pressure at Hospital Admission Is an Important Risk Factor in Models Predicting Outcome of COVID-19 Patients
por: Caillon, Antoine, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
por: Aguilar-Mahecha, Adriana, et al.
Publicado: (2021)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines
por: Hall, John S., et al.
Publicado: (2014)

Clinical Pharmacology of Hormonal Emergency Contraceptive Pills
por: Matyanga, Celia M. J., et al.
Publicado: (2018)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Transcriptional signatures of steroid hormones in the striatal neurons and astrocytes
por: Piechota, Marcin, et al.
Publicado: (2017)

The Proteomic Signature of Recombinant Growth Hormone in Recreational Athletes
por: Esefeld, Max, et al.
Publicado: (2021)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients
por: Wang, Rui, et al.
Publicado: (2014)

Validation of In Vitro Trained Transcriptomic Radiosensitivity Signatures in Clinical Cohorts
por: O’Connor, John D., et al.
Publicado: (2023)

Age and BMI Adjusted Comparison of Reproductive Hormones in PCOS
por: Fakhoury, Hana, et al.
Publicado: (2012)

Clinical Pharmacokinetic Studies of Enzalutamide
por: Gibbons, Jacqueline A., et al.
Publicado: (2015)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6qa9e19pbingf499mkrlbsb8tv